Mark Coles

Professor of Immunology, University of Oxford

Mark Coles is Professor of Immunology at the Kennedy Institute of Rheumatology, affiliated faculty in the Wolfson Centre for Mathematical Biology, and a member of the MRC Centre of Excellence in Exposome Immunology at the University of Oxford.

He is co-founder of Mestag Therapeutics and Lightox Ltd. Research in his group focuses on the application of human experimental medicine to immune-mediated inflammatory disease.